

a 79131
2



**WORLD HEALTH ORGANIZATION
ORGANISATION MONDIALE DE LA SANTE**

**WHO/BS/03.1957
corr. 1**

**EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION
Geneva, 17-21 February 2003**

**PROPOSAL TO ESTABLISH A NEW INTERNATIONAL
STANDARD AND THREE NEW REFERENCE REAGENTS FOR
THE MAPREC TEST OF POLIOVIRUS TYPE 2.
REPORT OF A WHO COLLABORATIVE STUDY.**

G. Dunn and A.B. Heath, National Institute for Biological Standards and Control,
Potters Bar, UK
D.J. Wood, Quality Assurance and Safety of Biologicals, Vaccines and Biologicals,
World Health Organization, Geneva, Switzerland
K. Chumakov, Center for Biologic Evaluation and Research, FDA, Bethesda USA

During its review of WHO/BS/03.1957 the Expert Committee noted that the proposed names for the reference materials were not consistent with the convention used by WHO. In accordance with the wishes of the Committee the proposed names for the reference materials have been modified, and now are as follows:

© World Health Organization 2003

All rights reserved. Publications of the World Health Organization can be obtained from Marketing and Dissemination, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to Publications, at the above address (fax: +41 22 791 4806; email: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.

WHO/BS/03.1957

corr. 1

- The preparation, in ampoules coded 97/758, is proposed as the First International Standard for MAPREC assay of poliovirus type 2 with an activity of 0.67% 481-G per ampoule.
- The preparation, in ampoules coded 98/596, is proposed as the First Reference Reagent (high mutant virus) for MAPREC assay of poliovirus type 2 with an activity of 1.21% 481-G per ampoule.
- The preparation, in ampoules coded 97/756, is proposed as the First Reference Reagent (low mutant virus) for MAPREC assay of poliovirus type 2 with an activity of 0.65% 481-G per ampoule.
- The preparation, in ampoules coded 98/524, is proposed as the First Reference Reagent (100% 481-G) for MAPREC assay of poliovirus type 2 with an activity of 93.5% 481-G per ampoule.

= = =